Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NILE: Liquid biopsy bests tissue testing for targetable mutations in NSCLC

Key clinical point: Liquid biopsy is more effective and faster than tissue-based genotyping for identifying targetable mutations in advanced non–small cell lung cancner.

Major finding: The cell-free DNA test detected relevant mutations in 77 patients versus 60 patients with tissue testing – and at a median of 9 versus 15 days. Additionally, the cell-free DNA results were delivered significantly faster than the standard of care tissue results (median, 9 vs. 15 days).

Study details: A prospective multicenter study of 282 non–small cell lung cancer patients.

Disclosures: This study was funded by Guardant Health. Dr. Papadimitrakopoulou serves on the advisory boards of several pharmaceutical companies. She reported receiving CME speaker fees from F. Hoffmann–La Roche, and has received research support from Eli Lilly, Novartis, Merck, AstraZeneca, F. Hoffmann–La Roche, Nektar Therapeutics, Janssen, Bristol-Myers Squibb, Checkmate, Incyte and Guardant Health.


Source: Papadimitrakopoulou VA et al. AACR 2019, Abstract 4460.